[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urologic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urologic-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,45,73,112,148,176,203,227,258,278,301,332,368,402,423,443,465,487,518,539,563,582,602,621],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100305626","phase-1-safety-and-feasibility-study-of-autologous-engineered-urethral-constructs-for-the-treatment-of-strictures-100305626",false,"NCT03258658","Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures","A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral","Inclusion Criteria:\n\n* Stricture of the urethra meeting the following criteria:\n\n  a) History of at least one 15-60 mm in length, as determined by urethrography. c) Contains at least 1 strictured segment through which a 16 Fr flexible cystoscope cannot be atraumatically passed.\n* Patients must be available for all follow-up visits.\n* Ability to speak English.\n\nExclusion Criteria:\n\n* Strictures of the meatus or prostatic urethra; any urethral stricture associated with or suspected to be urethral carcinoma, or strictures due to pelvic distraction injuries. Strictures \\\u003C10 mm or \\>60 mm, as determined by urethrography, and criteria for bulbar urethral strictures excluding those with strictures \\\u003C20 mm and \\>60 mm, as described by urethrography.\n* Presence of untreated urinary tract infection.\n* Presence or prior history of lichen sclerosis et atrophicus (previously termed 'balanitis xerotica obliterans').\n* Uncontrolled bleeding disorder or patients with a platelet count less than 50,000, hemophilia or patients routinely receiving blood products for bleeding disorders.\n* Any urological condition that would be likely to require additional urethral instrumentation during the period of investigation, including, but not limited to benign prostatic hyperplasia requiring treatment, use of alpha blockers, active prostate cancer, an unevaluated elevated prostate surface antigen (PSA), bladder cancer, or any recurrent urinary stone formation. Patients with evidence or diagnosis of any coagulation disorder (including concomitant anti-coagulation therapy at enrollment).\n* Serum creatinine \\> 2.0 mg\u002Fdl or evidence of progressive renal disease.\n* Patients with abnormal urologic conditions, including vesicoureteral reflux, bladder stones, bladder tumors and renal impairment.\n* Subjects with an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \\>3 times the upper limit of normal.\n* Subjects with an albumin value \\\u003C3.0 g\u002FdL.\n* Subjects with uncontrolled diabetes, unstable cardiac and\u002For pulmonary disorders.\n* Subjects with active tuberculosis (TB) requiring treatment in the past 3 years. Subjects with a current positive (≥5 mm induration for high-risk subjects; otherwise ≥10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.\n* Subjects known to be colonized with either methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), or gentamicin-resistant organisms.\n* Immunocompromised subjects or subjects receiving immunosuppressive agents (inhaled corticosteroids and chronic low-dose corticosteroids \\[≤0.25 mg\u002Fkg prednisone or equivalent per day\\] are permitted).\n* Any history of alcohol and\u002For drug abuse.\n* Current smoker.\n* Documented history of, or positive result of HIV, Hepatitis B or C, or any infectious disease. External signs, sequelae, or positive serology of sexually transmitted disease (including HPV).\n* Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study.\n* Concurrent participation in any other clinical investigation during the period of this investigation. Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study.\n* Any current illness that might confound the results of this investigation, including but not limited to bladder atonia, neuropathic\u002Fneurogenic bladder, bladder outlet obstruction (other than urethral stricture), sphincteric dysfunction, or spinal cord injury.\n* Any circumstance in which the investigator deems participation in the study is not in the subject's best interest.\n* Inability to participate in all necessary study activities due to physical or mental limitations.\n* Inability or unwillingness to return for all required follow-up visits.\n* inability or unwillingness to sign informed consent.\n* Patients requiring concomitant use of or treatment with immunosuppressive agents.\n* Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease).","MALE","21 Years","75 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase I clinical study to determine the safety and efficacy of using autologous, engineered urethral constructs for the treatment of urethral strictures in adult males.\n\nThe proposed study design is a prospective non-randomized and uncontrolled single-center investigation. Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to seed tubular PGA scaffolds to create autologous urethral constructs for the repair of urethral strictures.",[27,28,29,30],"Urologic Diseases","Male Urogenital Diseases","Urethral Stricture","Urethral Injury",[29],"RECRUITING","2026-06-03",{"date":35,"type":36},"2026-06-04","ACTUAL",{"date":38,"type":21},"2026-08",{"date":40,"type":21},"2029-12",{"name":42,"class":43},"Wake Forest University Health Sciences","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100506789","phase-2-examining-the-effects-of-intra-detrusor-botox-at-time-of-holep-in-men-with-overactive-bladder-symptoms-100506789","NCT05878951","Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms","A Multicenter Randomized Controlled Trial Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms","Inclusion Criteria:\n\n* Males 18 -89 undergoing HoLEP\n* Component of OAB symptoms including frequency, nocturia, urgency, and\u002For urge related incontinence\n* Willing to sign the Informed Consent Form\n* Able to read, understand, and complete patient questionnaires.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to OnabotulinumtoxinA injections\n* Patients having a concurrent ureteroscopy +\u002F- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP\n* Anticipated need for perineal urethrostomy at the time of HoLEP\n* Prior pelvic radiation or patients with a history of bladder cancer with or without BCG therapy\n* Patients who lack decisional capacity\n* Active urinary tract infection","18 Years","89 Years",{"count":55,"type":21},66,[57,58],"PHASE2","PHASE3","The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.",[61,62,63,27],"Urinary Incontinence","Overactive Bladder Syndrome","Overactive Bladder","2026-06-02",{"date":35,"type":36},{"date":67,"type":36},"2023-07-13",{"date":69,"type":21},"2026-12-31",{"name":71,"class":43},"Northwestern University",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":72},"100626454","effect-of-comprehensive-spa-care-on-kidney-and-urological-conditions-a-clinical-study-in-adult-patients-100626454","NCT07435844","Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients","Objective Assessment of the Effect of Comprehensive Spa Care on Patients With Chronic Kidney and Urological Diseases: A Prospective Interventional Clinical Study","Uro-Nefro","Inclusion Criteria:\n\n* Male or female aged 40 to 70 years\n* Prescribed comprehensive spa care (KLP) for one of the following indications: recurrent and chronic non-tuberculous inflammation of the kidneys and urinary tract resistant to antibiotic and pharmacological treatment, with at least 12 months of continuous urological care (indication VIII\u002F1); cystic kidney disease (indication VIII\u002F1); nephrolithiasis without urinary tract obstruction or nephrocalcinosis (indication VIII\u002F2); conditions after kidney or urinary tract surgery, including endovesical procedures, complicated prostatectomy, nephrolithotripsy, or recovery after extracorporeal shock wave lithotripsy (indication VIII\u002F3); chronic prostatitis or chronic prostatovesiculitis resistant to pharmacological and antibiotic treatment, with at least 12 months of continuous urological care (indication VIII\u002F4)\n* Able to walk from the sanatorium to the colonnade and back three times daily\n* Willing to follow the treatment plan\n* Signed informed consent\n\nExclusion Criteria:\n\n* Contraindications according to Czech Decree No. 2\u002F2015 Coll. on spa treatment criteria (pregnancy, acute illness, etc.)\n* Significant mobility limitation or severe neuropathy preventing daily walks to the colonnade\n* Significant obesity or inability to briefly hold breath (required for ultrasound examination)\n* Alcohol intake exceeding 20 g of ethanol per day\n* Nephrolithiasis with urinary tract obstruction\n* History of esophageal or gastric variceal bleeding\n* Severe comorbidities that could affect treatment outcomes\n* Active oncological disease\n* Unwillingness to adhere to the treatment plan","ALL","40 Years","70 Years",{"count":85,"type":21},150,[87],"NA","This is a single-arm, pretest-posttest study evaluating the effects of a 21-day comprehensive spa care (Komplexní lázeňská léčebně rehabilitační péče, KLP) on patients with nephrological and urological conditions treated at a spa facility in Mariánské Lázně, Czech Republic.\n\nThe study enrolls 150 adult patients (75 men and 75 women), aged 40-70 years, who are prescribed KLP for indications VIII\u002F1 (recurrent and chronic non-tuberculous inflammation of the kidneys and urinary tract), VIII\u002F2 (nephrolithiasis without urinary tract obstruction, nephrocalcinosis), VIII\u002F3 (conditions after kidney and urinary tract surgery), and VIII\u002F4 (chronic prostatitis or prostatovesiculitis resistant to pharmacological treatment).\n\nThe spa treatment consists of the use of natural healing resources of Mariánské Lázně, including a mineral spring drinking cure, balneotherapy (mineral water baths), peloid therapy, carbon dioxide therapy, climatotherapy, exercise therapy, and dietotherapy. The standard treatment duration is 21 days, during which each patient receives a total of 63 therapeutic procedures and drinks mineral spring water three times daily.\n\nPatients undergo assessments at the beginning (days 1-3) and at the end (days 19-21) of their treatment. Assessments include physical examination, abdominal and urinary tract ultrasound, blood and urine sampling with laboratory analysis, body composition measurement using bioelectrical impedance analysis (InBody), and psychometric questionnaire surveys.\n\nThe primary aim of the study is to objectively assess the therapeutic effect of comprehensive spa care on nephrological and urological diseases by comparing pre-treatment and post-treatment clinical, laboratory, and patient-reported outcomes.\n\nThe study was approved by the Ethics Committee of the University Hospital and Faculty of Medicine in Pilsen (decision of November 2, 2023, ref. no. 437\u002F23).",[27,90,91,92,93,94],"Urinary Tract Infections","Nephrolithiasis","Nephrocalcinosis","Prostatism","Kidney Diseases",[96,97,98,99,100,101,102],"Balneotherapy","Spa Treatment","Mineral Water Drinking Cure","Mariánské Lázně","Nephrology","Urology","comprehensive spa care","2026-04-21",{"date":105,"type":36},"2026-04-24",{"date":107,"type":36},"2026-04-07",{"date":109,"type":21},"2027-04-30",{"name":111,"class":43},"Institute of Spa and Balneology, public research institution",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":81,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":133,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100634125","the-voided-urinary-perineal-and-faecal-microbiota-among-children-and-adolescents---the-ppuf-study-100634125","NCT07535619","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents - the PpUF-study.","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children and Adolescents - the PpUF-study.","Inclusion Criteria:\n\n* Overactive bladder as per International Children's Continence Society criteria (cases only).\n* At least two wet days per week (cases only).\n* No prior pharmacological treatment of OAB and DUI (cases only).\n* No lower urinary tract symptoms (healthy participants only).\n* Negative urine dipstick test\n\nExclusion Criteria:\n\n* No known urogenital abnormality affecting the lower urinary tract function.\n* No known gastrointestinal or neurological diseases.\n* No use of systemic drugs within five half-lives of the drug.\n* No use of systemic antibiotics within three months before inclusion\n* No current urinary tract infection.\n* No urinary tract infection within the last three months prior to inclusion.\n* No current constipation.\n* Abnormal uroflowmetry (healthy participants only).",true,"5 Years","17 Years",{"count":123,"type":21},110,"OBSERVATIONAL","The aim of this study is to investigate whether the voided urinary, perineal\u002Fpreputial, and the fecal microbiota are different between children suffering from Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy children without bladder symptoms. Moreover, the study aims to investigate if the microbiota is different according to the severity of DUI and if the microbiota is changed throughout treatment of DUI. A follow-up study will as well be performed on healthy children to investigate how the microbiota evolves with increasing age and pubertal stage. Children with OAB and DUI will be recruited from involved pediatric departments, and specimen in the form of urine, perineal\u002Fpreputial swabs, and feces will be collected according to the protocol.",[61,127,128,27,129,130,131,132],"Daytime Wetting","Urination Disorders","Lower Urinary Tract Symptoms","Urological Manifestations","Elimination Disorders","Behavioral Symptoms",[134,135,136,137],"Voided Urinary Microbiota","Perineal Microbiota","Fecal Microbiota","Illumina MiSeq Sequencing","2026-04-15",{"date":140,"type":36},"2026-04-17",{"date":142,"type":36},"2022-12-14",{"date":144,"type":21},"2028-06",{"name":146,"class":43},"Aalborg University Hospital",4,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":119,"sex":81,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":147},"100515295","brain-activity-among-children-with-overactive-bladder-and-daytime-urinary-incontinence-and-healthy-children-100515295","NCT05989646","Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children","Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children, and Modulation of Brain Activity by Transcutaneous Electrical Nerve Stimulation - a Functional Magnetic Resonance Imaging Study","Inclusion Criteria:\n\n* Overactive Bladder as per International Children's Continence Society criteria (cases only).\n* At least 2 incontinence episodes per week (cases only).\n* No urinary tract symptoms (healthy participants only).\n* More than 3 daily urinations.\n* Normal clinical examination.\n\nExclusion Criteria:\n\n* Known urogenital abnormality affecting the lower urinary tract function.\n* Prior surgery in the urinary tract (except circumcision).\n* Known neurological diseases or prior cerebral surgery.\n* Known neuropsychiatric disorders or suspicion of those by screening.\n* Treatment with pharmacological agents affecting the brain function.\n* Prior treatment with Enuresis Alarm or Transcutaneous Electrical Nerve Stimulation.\n* Prior or current treatment with mirabegron or oxybutynin.\n* Current urinary tract infection.\n* Current constipation according to Rome IV-criteria or faecal incontinence.\n* Claustrophobia.\n* Metallic items in the body contraindicating MRI-scans.\n* Abnormal uroflowmetry (healthy participants only).","6 Years","14 Years",{"count":158,"type":21},65,[87],"The aim of this study is to investigate whether the activity in brain areas controlling the bladder is different among children suffering from Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy children without bladder symptoms. Moreover, the aim is to investigate if sacral transcutaneous electric nerve stimulation (TENS) has a central mechanism of action. Children with OAB and DUI will be recruited from involved pediatric departments, and functional magnetic resonance imaging (fMRI) will be performed before and after 10 weeks of sacral TENS. In healthy children without bladder symptoms, only the baseline fMRI will be performed.",[61,127,128,162,27,129,130,132,163,131],"Urination Involuntary","Mental Disorders",[165,166,167,168],"Transcutaneous Electrical Nerve Stimulation","TENS","Functional Magnetic Resonance Imaging","fMRI",{"date":170,"type":36},"2026-04-20",{"date":172,"type":36},"2021-05-05",{"date":174,"type":21},"2027-12",{"name":146,"class":43},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":72},"100321313","phase-1-bioengineered-penile-tissue-constructs-for-irreversibly-damaged-penile-corpora-100321313","NCT03463239","Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora","Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora","Inclusion Criteria:\n\n1. Males aged 18-60 years.\n2. Acquired structural abnormalities of the corpora cavernosum secondary to trauma, infection, inflammation, or fibromatosis. These abnormalities will be diagnosed by clinical examination, and\u002For ultrasound, and\u002For computerized tomography.\n3. Stable abnormalities - at least 6 months with no pain or changes in deformity.\n4. At least one failed attempt at management by conventional approaches at least 6 months prior to enrollment\n5. Deformities less than 5 cm in length.\n6. Written informed consent obtained prior to participation in the study.\n7. Patients must be available for all follow up visits.\n8. Ability to speak English.\n\nExclusion Criteria:\n\n1. Presence of untreated or incompletely treated urinary tract infection at the time of biopsy.\n2. Uncontrolled bleeding disorder or patients with a platelet count less than 50,000, hemophilia or patients routinely receiving blood products for bleeding disorders.\n3. Serum creatinine \\> 2.0 mg\u002Fdl or evidence of progressive renal disease.\n4. ALT or AST value \\>1.5 times the upper limit of normal.\n5. Albumin \\\u003C 3.0 g\u002FdL.\n6. Serum direct bilirubin \\>0.3 mg\u002FdL OR total bilirubin \\> 1.4 mg\u002FdL\n7. BM I\\>40 kg\u002Fm2\n8. Uncontrolled diabetes with HbA1C\\>9%. (Subjects with controlled diabetes must be under care of diabetologist with treatment goals consistent with ADA criteria).\n9. Unstable cardiac disorders within the past 6 months including angina, abnormal ECG, history of cardiac arrest, surgery and\u002For other interventional procedure.\n10. Unstable pulmonary disorders within the past 6 months including dyspnea on exertion, chronic productive cough, pneumonia, hemoptysis, asthma requiring nebulized therapy.\n11. Active tuberculosis (TB) requiring treatment in the past 3 years. Subjects with a current positive (≥5 mm induration for high-risk subjects; otherwise ≥10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.\n12. Known to be colonization with either methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), or gentamicin-resistant organisms.\n13. Immunocompromised subjects or subjects receiving immunosuppressive agents.\n14. Any history of alcohol and\u002For drug abuse.\n15. Documented history of, or positive result of HIV, Hepatitis B or C, or any infectious disease. External signs, sequelae, or positive serology of sexually transmitted disease (including HPV). Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study.\n16. Concurrent participation in any other clinical investigation during the period of this investigation. Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study.\n17. Any circumstance in which the investigator deems participation in the study is not in the subject's best interest.\n18. Inability to participate in all necessary study activities due to physical or mental limitations.\n19. Inability or unwillingness to return for all required follow-up visits, for instance life expectancy \\\u003C 1 year, or subject who knows they will be moving out of the country and unable to return for follow-up visits.\n20. Inability or unwillingness to sign informed consent.\n21. Patients requiring concomitant use of or treatment with immunosuppressive agents\n22. Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease).","60 Years",{"count":20,"type":21},[24],"The primary objective of this clinical trial is to evaluate the safety of autologous engineered corpora cavernosa + albuginea constructs for treatment of complex penile deformities. Autologous endothelial and smooth muscle cells obtained from enrolled subjects' corpora cavernosa biopsy sample, will be culture expanded in vitro and used to seed decellularized corpora cavernosa + albuginea obtained from cadaveric-donors to create autologous bioengineered corpora cavernosa\u002Falbuginea constructs for repair of damaged penile tissues.",[27,28,188,189,190,191],"Penile Diseases","Corpus Callosum Malformation","Corpora Cavernosa; Inflammation","Trauma Injury",[193],"Autologous tissue engineered corpora","NOT_YET_RECRUITING","2026-03-26",{"date":197,"type":36},"2026-03-27",{"date":199,"type":21},"2026-10",{"date":201,"type":21},"2030-12",{"name":42,"class":43},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":44},"100463380","evaluation-patient-satisfaction-after-passive-bladder-catheter-removal-compared-to-active-removal-100463380","NCT05313945","Evaluation Patient Satisfaction After Passive Bladder Catheter Removal Compared to Active Removal","Multicenter, Randomized, Controlled Trial Evaluating Patient Satisfaction After Passive Bladder Catheter Removal Following Urological Surgery Compared to Active Removal by a Nurse","IDESONDE","Inclusion Criteria:\n\n1. Male ≥ 18 years old\n2. With an indwelling urinary catheter placed after any of the following procedures:\n\n   A uro-endoscopic surgery from the list below:\n   * Endoscopic prostate resection (or transurethral prostate resection).\n   * Laser prostate enucleation\n   * Prostate thermotherapy by radiofrequency\n   * A high-intensity focused ultrasound treatment for prostate cancer\n   * Cervico-prostatic incision or internal urethrotomy\n   * Endoscopic\u002FTransurethral Resection of Bladder Tumor (TURBT)\n   * Surgical treatment of bladder stones, ureter stones (rigid ureteroscopy) and kidney stones (flexible ureteroscopy with laser stone fragmentation)\n3. Patient who has given written consent to participate\n\nExclusion Criteria:\n\n1. Patient who is unable to perform intimate hygiene alone in a standing position\n2. Patient with a painful genital lesion\n3. Patient with an extended pelvic pathology\n4. Need to remove the indwelling urinary catheter at the patient's home instead of hospital\n5. Patient under guardianship or curator\n6. Patient unable to understand the objectives of the study or unwilling to comply with postoperative instructions",{"count":212,"type":21},160,[87],"In usual practice, the removal of the bladder catheter is performed by a nurse a few days after the surgery. The nurse deflates the balloon and removes the catheter from the urethra by manual traction. To date, there are no solid data on the impact of passive catheter removal on patient satisfaction.\n\nIt is therefore necessary to estimate the effect on patient satisfaction of active catheter removal by a nurse versus passive catheter removal under gravity. The effect on pain and anxiety will also be compared between the two techniques. The methodology used was that of an open-label randomized controlled trial.",[27],[217],"bladder catheter","2026-03-13",{"date":220,"type":36},"2026-03-16",{"date":222,"type":36},"2022-07-21",{"date":224,"type":21},"2027-03-21",{"name":226,"class":43},"Hospices Civils de Lyon",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":81,"minAge":52,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":237,"conditions":238,"keywords":244,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":72},"100623315","a-study-of-ward-admissions-for-haematuria-100623315","NCT07395037","A Study of Ward Admissions for Haematuria","Ward AdmiSsion of Haematuria: an Observational mUlticentre sTudy","WASHOUT","Inclusion Criteria:\n\n* Patients are included if they are over 16 years of age or older and admitted to a participating urological secondary care centre\n* admitted as an emergency with haematuria as the primary or secondary diagnosis under the primary or joint care of urology\n\nExclusion Criteria:\n\n* any patients under 16 years of age\n* patients with catheter-related urethral trauma (defined as haemturia immediately after insertion of a urethral catheter that was documented as traumatic by the clinician, with no previous history of haemturia prior to catheter insertion)\n* patients that are in hospital less than 24 hours.",{"count":236,"type":21},1050,"This multicenter, prospective observational study will evaluate national and international practice variations (if present) in the emergency management of patients admitted to hospital with haematuria, inform a consensus guideline for best practice and provide evidence to design an implementation study to optimise haematuria management pathway.",[27,239,240,241,242,243],"Hematuria","Hematuria; Benign","Bladder Cancer","Renal Cancer","Urothelial Carcinoma",[245,246,247,248],"catheter","haematuria","hematuria","irrigation","2026-02-03",{"date":251,"type":36},"2026-02-09",{"date":253,"type":36},"2024-01-01",{"date":255,"type":21},"2026-04-30",{"name":257,"class":43},"British Urology Researchers in Surgical Training",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":81,"minAge":52,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":72},"100520671","active-informed-consent-a-new-solution-to-improve-and-objectively-test-the-patient-understanding-of-complex-surgical-procedures-proposals-100520671","NCT06059599","Active Informed Consent: a New Solution to Improve and Objectively Test the Patient Understanding of Complex Surgical Procedures Proposals","Inclusion Criteria:\n\n* Adults aged ≥ 18 years (with full legal capacity to consent).\n* Scheduled for elective surgery in one of the two domains: spinal surgery or radical prostatectomy in the waiting list of our centers.\n* Ability to comprehend Italian language.\n* Basic computer or internet access skills. Patients (or their family members) should have the ability to access multimedia content.\n\nExclusion Criteria:\n\n* Patients under age: minors.\n* Inability to provide informed consent or self-determination (significant cognitive impairment, severe mental illness, or decisional incapacity that would prevent them from understanding the consent materials or participating in the decision-making).\n* Urgent or emergency surgery cases.",{"count":265,"type":21},300,[87],"This is an interventional, non-pharmacological, randomized controlled superiority study (RCT), multicenter, open label, parallel group.\n\nThe aim is to evaluate the effectiveness of a new preoperative information method, based on multimedia tools and on the objective control of understanding by the patient candidate for spinal or urological surgery.",[269,27],"Spine Disease","2026-01-29",{"date":272,"type":36},"2026-02-02",{"date":274,"type":36},"2024-06-19",{"date":199,"type":21},{"name":277,"class":43},"Istituto Ortopedico Rizzoli",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":81,"minAge":52,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":72},"100622033","evaluation-of-ai-large-models-for-diagnosis-and-treatment-in-real-world-cases-multicenter-retrospective-study-100622033","NCT07378358","Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study","Inclusion Criteria:\n\n* The case data is sourced from the four hospitals involved in the study, with complete and authentic diagnosis and treatment records.\n* Patients must be 18 years or older, with no gender restrictions.\n* Complete medical records, including the following core information: patient' s basic information, present illness history, past medical history, physical examination, and auxiliary examinations (including laboratory and imaging tests).\n* A clear discharge diagnosis and treatment plan (including therapeutic measures and follow-up arrangements).\n* Medical records have been archived, with objective and accurate information that has not been altered.\n* The patient or their legal representative has provided informed consent, agreeing to the use of their anonymized medical data for research analysis.\n\nExclusion Criteria:\n\n* Medical records with significant missing information, such as key clinical details (present illness history, diagnostic or treatment records, etc.).\n* Cases where the diagnosis or treatment plan is unclear, or where treatment has not been fully completed for an initial diagnosis.\n* Cases where the primary diagnosis is not urological.\n* Cases with major errors or inconsistencies in the records that could affect further assessment.\n* Medical records in special formats or images that are not readable (e.g., handwritten notes, non-standard documentation).\n* Patients who have not signed the informed consent form or who refuse to allow their medical data to be used for research.",{"count":285,"type":21},800,"This multicenter retrospective study aims to evaluate the diagnostic and therapeutic performance of three large language models-ChatGPT, Gemini and Deepseek-using 800 archived inpatient medical records from urology departments across four tertiary hospitals. The study will focus on the accuracy and applicability of these models in disease recognition, preliminary diagnosis and treatment recommendation generation, in order to explore their potential value and limitations in supporting clinical decision-making in real-world settings.",[27],[289,27,290,291],"Large Language Models","Clinical Decision Support","Retrospective Study","2026-01-26",{"date":294,"type":36},"2026-01-30",{"date":296,"type":21},"2026-01-01",{"date":298,"type":21},"2026-06-01",{"name":300,"class":43},"First Affiliated Hospital of Fujian Medical University",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":81,"minAge":52,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":320,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":72},"100618951","virtual-reality-induced-pain-and-anxiety-relief-in-outpatient-urological-procedures-100618951","NCT07338292","VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures","VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures: a Post-marketing Clinical Investigation of REALICA","Inclusion Criteria:\n\n* Male\u002Ffemale with age ≥ 18 years\n* Patient who are undergoing one of the interventions mentioned in the study for the first time;\n* Eligibility for minimally invasive ambulatory urological procedures, possibly requiring vascular access (circumcision, prostate biopsy, flexible cystoscopy);\n* Ability to understand instructions and complete study questionnaires;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Absolute contraindications to the planned urological procedure (e.g., active urinary tract infection, anatomical urethral abnormalities);\n* Recent urological manipulations (e.g., urethral dilation, bladder biopsy, insertion or removal of a double-J stent);\n* Medical contraindications to the use of virtual reality, including uncontrolled photosensitive epilepsy and relevant neurological, ophthalmologic, or otolaryngologic disorders;\n* Presence of severe psychiatric disorders or major cardiovascular diseases that may interfere with study participation;\n* Previous adverse reactions to virtual reality exposure;\n* Use of analgesic medications within 24 hours prior to the procedure;\n* Use of drugs that may alter consciousness or impair the ability to complete psychological assessments;\n* Severe communication disabilities or significant hearing impairment that would prevent completion of questionnaires.","99 Years",{"count":310,"type":21},56,[87],"Though the efficacy of VRH is documented in various outpatient urological procedures and has provided promising preliminary information in prostate biopsy, its systematic use in urology remains poorly studied. Considering the potential of invasive urological procedures to induce significant patient discomfort, the application of innovative immersive approaches, such as those offered by medical devices, could lead to an overall clinical benefit. Among these, REALICA® (available from https:\u002F\u002FREALICA.io\u002Fen\u002F), a class I CE medical device, widely used in hospitals and validated by numerous studies, represents a valuable resource in urology, supported by high satisfaction rates received in abdominal surgery and extracorporeal lithotripsy",[27,314,315,316,317,318,319],"Prostate Biopsy","Flexible Cystoscopy","Circumcision","Stress","Anxiety","Pain",[321,322],"virtual reality","medical device","2026-01-07",{"date":325,"type":36},"2026-01-13",{"date":327,"type":36},"2025-12-17",{"date":329,"type":21},"2026-10-31",{"name":331,"class":43},"Istituto Oncologico Veneto IRCCS",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":81,"minAge":52,"maxAge":339,"enrollmentInfo":340,"targetDuration":342,"studyType":124,"phases":4,"briefSummary":343,"conditions":344,"keywords":355,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":72},"100568077","vorolanib-in-the-second-line-treatment-of-patients-with-unresectable-or-metastatic-renal-cell-carcinoma-100568077","NCT06676527","Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n* Subjects have fully understood and voluntarily signed the informed consent form (ICF);\n* 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;\n* Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;\n* According to RECIST (version 1.1), there are targets that are considered to be observable;\n* The main organs function well.\n\nExclusion Criteria:\n\n* A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);\n* Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;\n* Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;\n* A history of severe drug allergy, including but not limited to antibody drugs;\n* Patients with contraindications for immunotherapy restart;\n* A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;\n* Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion\u002Fexclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;\n* Have central nervous system metastases and\u002For cancerous meningitis;\n* Known history of clinically significant liver disease, including those infected with viral hepatitis activity;\n* Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);\n* Patients with any severe and\u002For uncontrolled disease;\n* Renal failure requires hemodialysis or peritoneal dialysis;\n* Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;\n* History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;\n* Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;\n* Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.","80 Years",{"count":341,"type":21},39,"12 Weeks","This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.",[345,346,347,348,349,28,350,94,27,351,352,353,354],"Neoplasms","Kidney Neoplasms","Urologic Neoplasms","Urogenital Neoplasms","Female Urogenital Diseases","Urogenital Diseases","Carcinoma","Renal Cell Cancer","Carcinoma, Renal Cell","Antineoplastic Agents",[356,357,358],"observational study","clear cell Renal Cell Carcinoma","TKIs","2025-12-04",{"date":361,"type":36},"2025-12-05",{"date":363,"type":36},"2024-09-01",{"date":365,"type":21},"2026-09-01",{"name":367,"class":43},"Jinling Hospital, China",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":377,"briefSummary":378,"conditions":379,"keywords":387,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":44},"100475177","pact-programme-for-parents-of-children-with-shcn-100475177","NCT05467527","PACT Programme for Parents of Children With SHCN","Effectiveness of Prosocial-orientated Acceptance and Commitment Training (PACT) Programme for Parents of Children With Special Health Care Needs in Response to Outbreaks of Novel Infectious Disease: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Cantonese-speaking Hong Kong residents\n* Living together with the child who is at preschool\u002Fschool-age (3-8 years old)\n* Caregivers who adopted the responsibility of taking care of the child,\n* has daily access to their iPhone and Android smartphones.\n\nIn addition, potential eligible parents who respond \"yes\" to any of the five validated screening questions in the Children with Special Health Care Needs (SHCN) Screener (see https:\u002F\u002Fwww.childhealthdata.org\u002Fdocs\u002Fcshcn\u002Ftechnical-summary-of-cshcn-screener.pdf) will then be asked the associated follow-up questions to determine whether the child possesses physical, neurodevelopmental\u002Femotional problem(s) that has lasted for at least 12 months. Only children with a positive response(s) to ≥ 1 item in each of the associated follow-up questions will be classified as children with SHCN.\n\nExclusion Criteria:\n\n* Parents who have diagnoses of severe mental illness or developmental disabilities, such as intellectual disabilities",{"count":376,"type":21},196,[87],"This randomised controlled trial aims to determine the efficacy of a 12-week, smartphone-based Prosocial-orientated Acceptance and Commitment Training (PACT) programme plus age-appropriate positive parenting advice on the psychological flexibility, prosociality, parenting competence and family functioning with parents of children with special health care needs as well as the mental well-being of parent-child dyads over 12 months follow-up.",[27,380,381,382,383,384,385,386],"Gastrointestinal Diseases","Vascular Diseases","Cleft Lip and Palate","Neurodevelopmental Disorders","Attention Deficit Hyperactivity Disorder","Autism Spectrum Disorder","Developmental Delay",[388,389,390,391,392],"Acceptance and Commitment Therapy","Randomised Controlled Trial","Special health care needs","novel infectious disease","prosociality","2025-08-08",{"date":395,"type":36},"2025-08-13",{"date":397,"type":36},"2022-06-27",{"date":399,"type":21},"2025-12-31",{"name":401,"class":43},"Chinese University of Hong Kong",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":119,"sex":81,"minAge":52,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":72},"100478299","patient-satisfaction-of-virtual-vs-in-person-workup-and-treatment-of-lower-urinary-tract-symptoms-100478299","NCT05508165","Patient Satisfaction of Virtual vs In-Person Workup and Treatment of Lower Urinary Tract Symptoms.","IRB: #12530 Prospective, Randomized Study to Assess Clinical Outcomes and Patient Satisfaction of Virtual vs. In-Person Workup and Treatment of Lower Urinary Tract Symptoms","Inclusion Criteria\n\n* ≥18 years of age\n* New patient referral for urinary retention, BPH, or LUTS (Cohort 1)\n* Established patient for urinary retention, BPH, or LUTS (Cohort 2)\n* Male\n\nExclusion Criteria\n\n* \\\u003C18 years of age\n* Inability to provide informed consent\n* Visually or hearing impaired\n* Concomitant condition requiring in-person exam or evaluation\n* History of allergic reaction or issues with ultrasound gel",{"count":410,"type":21},60,[87],"This study is being done to compare usefulness of data collected in uroflowmetry, a test that measures the amount of urine released from the body, at home versus in the doctor's office. Additionally, investigators are assessing patient satisfaction when completing a virtual visit for lower urinary tract symptoms (LUTS), related to prostatic enlargement, compared to an in person visit.\n\nThe three devices being investigated have not been used in the home setting to make urinary measurements as is typically done in clinic. The goal is to test the effectiveness and accuracy of these devices compared to our standard clinical practices and demonstrate their ability to provide useful information in the home setting.",[27],"2025-03-11",{"date":416,"type":36},"2025-03-13",{"date":418,"type":36},"2022-08-30",{"date":420,"type":21},"2026-12-30",{"name":422,"class":43},"Indiana University",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":72},"100556927","laser-outcomes-associated-with-holmium-laser-enucleation-of-the-prostate-holep-procedures-100556927","NCT06531473","Laser Outcomes Associated With (Holmium Laser Enucleation of the Prostate) HoLEP Procedures","Laser Outcomes Associated With HoLEP Procedures","Inclusion Criteria:\n\n* Males 18-89 who are undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms, that are typically caused by enlarged prostates\n\nExclusion Criteria:\n\n* Prostates measurements over 200g\n* Patients who lack decisional capacity\n* Patients who are non-english speakers",{"count":265,"type":21},[87],"The primary aim is to assess the impact of laser setting frequency and wattage during holmium laser enucleation of the prostate. There is currently no gold-standard laser settings for HoLEP procedures. In the investigator's current high-volume practice, the following settings for enucleation are: 2j 50hz. These settings are conventional settings, but there is no literature to prove optimal laser settings. The investigators hypothesizes that utilization of higher laser settings may be associated with a clinically significant (defined as \\> 10%) decrease in procedural time without any detrimental postoperative outcomes, and a utilization of lower laser settings may be associated with a clinically significant (defined as \\>10%) reduction in postoperative irritative voiding symptoms without any detrimental postoperative outcomes.",[27,434],"Prostate Obstruction","2024-11-12",{"date":437,"type":36},"2024-11-14",{"date":439,"type":36},"2024-03-04",{"date":441,"type":21},"2026-08-30",{"name":71,"class":43},{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":81,"minAge":52,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":464},"100432317","development-of-a-new-canadian-endourology-group-stent-symptom-score-100432317","NCT04909541","Development of a New Canadian Endourology Group Stent Symptom Score","Canadian Endourology Group Stent Symptom Score: Development and Validation of A New Questionnaire","CEGSSS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient with ureteral stent\n* Ability to communicate in English\n\nExclusion Criteria:\n\n* Inability to provide an informed consent due to physical or mental inability\n* Active malignancy\n* Obstruction\n* Long-term stent (\\>2 weeks)",{"count":452,"type":21},180,"Placement of a ureteral stent is a common urological intervention. For decades there was no valid measures available to assess quality of life issues in patients with ureteral stents, which has hampered the understanding of such symptoms and their true impact. In order to improve the outcomes associated with the placement of a stent, a validated tool is needed to measure its impact and the amount of undesirable effects it produces on patients requiring the placement of a stent. In 2003, the team of the Bristol Urological Institute developed a validated questionnaire called the: URETERAL STENT SYMPTOM QUESTIONNAIRE (USSQ). The questionnaire contains 38 items included in 6 sections. Despite the obvious need of a validated questionnaire, the latter remains unused by the community of peer urologists. Many of urologists consider it too long to be used in clinical practice and even for research purposes. This issue motivated the Canadian Endourology Group (CEG) to work collaboratively on the development of the CANADIAN ENDOUROLOGY GROUP STENT SYMPTOM SCORE (CEGSSS) in order to provide clinicians with a more useful and validated tool. To fulfill this objective, the CEG proceeds in three phases. Phase 1. A systematic, deliberative, and participatory approach mostly through face to face meetings, including patients, clinicians, and researchers in the field of Endourology to identify a minimum needs-based set of domains and items that are, clinically relevant to be included in the CEGSSS in order to ensure optimal uptake in the clinical setting. Phase 2. A pilot study to assess feasibility\u002Facceptability and further refine the proposed set of items selected in phase 1 of the study. Phase 3. A multicentric prospective study to evaluate the validity, reliability and sensitivity to change of the CEGSSS.\n\nThis research project is conducted by the Canadian Endourology Group (CEG), a panel of experts in the field of endourology in Canada. The CEG is a national member-based organization dedicated to enabling the profession to provide the highest possible standards of endourological care and to advance the science of endourology by collaboratively:\n\n1. Fostering excellence in endourological practice through advocacy, education, research and practice support tools,\n2. Leading evidence-based clinical practice through the development of practice standards and guidelines in endourology,\n3. Providing continuous professional development for Canadian endourologists along the career-path continuum,\n4. Providing leadership in public education for endourological conditions.",[27],"2024-06-06",{"date":457,"type":36},"2024-06-07",{"date":459,"type":36},"2022-05-15",{"date":461,"type":21},"2025-09-15",{"name":463,"class":43},"Centre hospitalier de l'Université de Montréal (CHUM)",9,{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":11,"sex":81,"minAge":52,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":72},"100546618","prom-project-urology-100546618","NCT06397287","PROM Project Urology","Standardized Collection of Patient Reported Outcomes (PROs) in Everyday Clinical Practice","Inclusion Criteria:\n\n1. Patients treated at the Department of Urology\n2. ≥18 years of age\n3. Active Mail-account, use of smartphone\u002Ftablet\u002FPC\n4. Written informed consent\n\nExclusion Criteria:\n\n\\- Patients who cannot give written consent and\u002For do not have digital competence (e.g. no active e-mail account)",{"count":473,"type":21},47,"All patients undergoing urological surgery or treatment should receive standardized questionnaires on quality of life, satisfaction, pain and physical recovery. Indication-specific, individual pathways are set up, for example, for patients with localized prostate cancer, benign prostate enlargement, bladder dysfunction or erectile dysfunction. In combination with the clinical data, the PROM data should help to improve the quality of the results and, if necessary, adapt treatment pathways to patient needs.",[476,27,477],"Surgery","Urologic Cancer","2024-04-29",{"date":480,"type":36},"2024-05-02",{"date":482,"type":36},"2023-09-05",{"date":484,"type":21},"2045-09-05",{"name":486,"class":43},"Medical University of Graz",{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":119,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":22,"phases":497,"briefSummary":498,"conditions":499,"keywords":507,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":72},"100543557","the-man-van-project-100543557","NCT06357416","The Man Van Project","The Man Van Project: An Evaluation of the Effectiveness of a Mobile Outreach Screening Clinic Model for Earlier Detection of Prostate Cancer and Other Male Cancers","MV","Patients are eligible to be included in the research study if they are eligible to access the Man Van mobile outreach clinic, which is a novel clinical service delivered by The Royal Marsden Hospital NHS Foundation Trust. The inclusion and exclusion criteria have been designed to be as broad as possible, in order to include data from as many patients using the Man Van clinical service as possible.\n\nAs the primary purpose of the Man Van mobile outreach clinic is to screen for prostate, testicular, penile and other cancers that affect men, only men are eligible to be reviewed in the mobile outreach clinic hence only males will be recruited into this study.\n\nInclusion criteria for the Main Study\n\n1. Participating in the linked Man Van mobile outreach clinic\n2. Age ≥45 years\n3. Male\n\n   (The initial pilot study had a age criteria of ≥18 years, but this was amended).\n\n   MV-POCT\n\n   Inclusion Criteria: Any patient having a PSA and\u002For an HbA1c test as part of a Man Van work up, or via the our rapid diagnostics clinic.\n\n   MV-QualQ\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment.\n\n   MV-Eco\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment.\n\n   MV-PRS\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment and able to provide saliva samples.\n\n   MV-DNA\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment, and able to provide blood\u002Fsaliva samples.\n\n   MV MV-UctDNA\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment, and able to provide urine samples.\n\n   MV-SSI\n\n   Inclusion criteria:\n   * Aged \\> 18 and over (on date of invitation to participate)\n   * Works for healthcare organisation, other stakeholder or professional or potential man van patient who was not seen or relative of a Man Van patient\u002Fpotential patient\n\n   Exclusion criteria:\n   * Man van patient who has attended appointment\n\n   MV-TPP\n\n   Inclusion criteria:\n\n   Healthcare Professionals\n   * Aged \\> 18 and over (on date of invitation to participate)\n   * Speaks English\n   * Works within the UK\n   * Profession: GPs, Practice Staff (Nurses, Physician Assistants and Associates\n   * Healthcare assistants)\n   * Experienced in adopting new tests and guidelines into practice.\n   * Experienced in detecting, managing, and referring symptoms and asymptomatic patients with symptoms of prostate, pancreatic, GI cancer and\u002For are at an increased risk of developing these cancers.\n\n   Patients\n   * Aged \\> 18 and over (on date of invitation to participate)\n   * Speaks English\n   * Lives in the UK\n   * Patients with direct and in-direct experience with prostate, pancreatic, GI cancers.\n   * Patients at an increased risk of developing prostate, pancreatic, GI cancer in accordance with known risk factors, which includes age, smoking, being overweight or obese, family history and genetic factors, pancreatitis, and diabetes.\n\n   Other key stakeholders\u002Fprofessionals\n\n   • Aged \\> 18 and over (on date of invitation to participate)\n\n   • Speak English\n   * Works within the UK\n   * Professions: medical devices and biomedical researchers, scientists, representatives for major regulatory and funding bodies\n   * Knowledgeable of Early Detection initiatives (tests, outreach programes)\n\n   Exclusion criteria:\n\n   GPs\n\n   • Individuals who are unwilling to take part in the study.\n   * Individuals with no experience in adopting new cancer tests and guidelines into practice.\n   * Individuals with no experience in in detecting, managing, and referring patients with symptoms of cancer and\u002For are at an increased risk of developing prostate, pancreatic, GI cancer.\n   * Individuals who do not adequately understand verbal explanations or written information in English.\n\n   Patients • Individuals who are unwilling to take part in the study.\n\n   • Individuals who do not adequately understand verbal explanations or written information in English.\n\n   • Unable to provide written and verbal consent.\n\n   • No direct or indirect lived experience with prostate, pancreatic, GI cancers.\n\n   Non-clinical key stakeholders\u002Fprofessionals • Individuals who are unwilling to take part in the study • Individuals who are not familiar with cancer biomarkers and medical tests • Individuals with no knowledge of early detection\n\n   • Individuals who do not adequately understand verbal explanations or written information in English",{"count":496,"type":21},4000,[87],"National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care at the site of their work and in their communities. The initial focus of this new standard of care clinic is to access workplaces with large manual workforces where large scale working from home is not possible. These will include logistics firms and bus companies. These companies employ large numbers of black and minority ethnic men who also have poorer outcomes with a range of other diseases, including Coronavirus disease (COVID)-19. The novel clinical service will collaborate with Unite (and other unions) as well as employers in order to reach our target groups effectively. There is also the opportunity to target higher risk groups e.g. Afro Caribbean communities whose rates of prostate cancer are 1 in 41 as well as occupational higher risk categories. The Man Van has the potential to swing the balance of evidence in favour of Prostate-Specific Antigen (PSA) screening, with a targeted screening program directed at high-risk groups including ethnic minorities and manual workers. Reasons for poorer outcomes amongst these groups are multi-factorial and complex. Levels of education are often a factor which can impact the understanding of the disease and how to seek assistance. Distrust of medical organisations has also been cited as a factor.\n\nThe aim of the Man Van mobile outreach service is to enable men access to a specific men's health service - focusing on general health and wellbeing (including BMI assessment, blood pressure, blood sugar\u002Fdiabetes checks etc) and a prostate check for those who raise concerns. This will include a PSA test where relevant. This will be the core data gathered from the project.\n\nPatients will receive PSA results in the 'Man Van' by a clinical nurse specialist with patients with raised PSA levels being referred into the standard rapid referral cancer pathways. Similar considerations will apply to men with haematuria detected on dip stick testing or who present with a testicular mass or penile lesion (both rare but important).\n\nThe clinical data generated from each routine health screening appointment will be analysed to determine the effectiveness of the Man Van mobile outreach model in identifying prostate and other male cancers and other co-morbidities much earlier than if patients had waited to present to their General Practitioner (GP) or other healthcare provider.\n\nPatients who receive an early diagnosis of clinically significant prostate cancer will have access to early curative treatments, which are typically less invasive and shorter in timescales. Similar interventions have shown large scale success in particular with breast and cervical cancer.\n\nThe NHS sees many patients accessing cancer care at a late stage. Reducing this trend is a key objective of the NHS Long Term Plan. The COVID-19 pandemic has further exacerbated health inequalities and mobile clinics can potentially be a model for alleviating this. To enable patients access to medical treatment earlier there is a need to make the 'seeking advice on men's health and prostate issues' less daunting, more normal and easily accessible. The 'Man Van' has the ability to do just that and it is anticipated that the findings of this research, using the data generated from each patient's routine health screening, will demonstrate that a mobile outreach model is more effective in identifying cancers at an earlier stage than 'traditional' diagnostic pathways.\n\nWe also hope to evaluate the Man Van with a qualitative study looking at the patient perspectives from those who utilise the Man Van.\n\nThe reasons for high risk in prostate cancer are heavily linked to genetics. This is an issue as there is less recruitment of high risk groups to studies. We hope to gather genetic data from a higher proportion of genetically susceptible men via the Man Van, which can be used in future to further genetic knowledge of prostate cancer.",[500,477,27,241,501,502,503,504,505,242,506],"Prostate Cancer","Diabetes","Hypertension","Mental Health Issue","Alcoholism","Smoking","Testis Cancer",[508,509],"mobile health","targeted screening",{"date":511,"type":36},"2024-05-01",{"date":513,"type":36},"2022-04-13",{"date":515,"type":21},"2026-12-01",{"name":517,"class":43},"Royal Marsden NHS Foundation Trust",{"id":519,"slug":520,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":119,"sex":81,"minAge":52,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":72},"100530522","bank-of-biological-material-from-patients-and-healthy-donors-for-the-study-of-urological-and-uro-oncological-pathologies-100530522","NCT06187870","Bank of Biological Material From Patients and Healthy Donors for the Study of Urological and Uro-oncological Pathologies","Creation of a Bank of Biological Material From Patients and Healthy Donors (Biobank) for the Study of Urological and Uro-oncological Pathologies - URBBAN","Inclusion Criteria:\n\n* Male and female patients with an age \\> 18\n* Ability to read and sign the informed consent\n* patients affected by urological or uro-oncological diseases\n\nExclusion Criteria:\n\n* People with an age \\\u003C 18\n* Incapacity to read and sign the informed consent",{"count":526,"type":21},15000,"The project aims to collect fresh biological material derived both from surgical resections performed in diseases, neoplastic and otherwise, of urological relevance at the level of the prostate, bladder, kidney, testicle and genitourinary organs, and from peripheral blood or other fluids biological samples such as urine, seminal fluid, buccal mucosa, feces or saliva, when available.",[27,477,529],"Infertility","2024-01-08",{"date":532,"type":36},"2024-01-10",{"date":534,"type":36},"2010-10-07",{"date":536,"type":21},"2030-10-06",{"name":538,"class":43},"IRCCS San Raffaele",{"id":540,"slug":541,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":119,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":72},"100530981","protocol-n-2014---observational-study-on-the-quality-of-life-of-outpatients-100530981","NCT06193850","Protocol N. 2014 - Observational Study on the Quality of Life of Outpatients","Observational Study on the Quality of Life of Patients Attending General Urology, Sexual Medicine, Reproductive Medicine, Uro-oncology, Neuro-urology, Functional Urology Clinics","Inclusion Criteria:\n\n* subjects belonging to general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.\n* subjects \\>= 18 years old\n* signature of informed consent\n\nExclusion Criteria:\n\n* \\- subjects \\\u003C 18 years\n* presence of mental or physical disability that may prevent the patient from answering the questionnaires.",{"count":547,"type":21},10000,"Prospective observational study on the quality of life of patients attending general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.The data relating to the clinical conditions (disease state, psychological and related to quality of life) of the patients belonging to the above-mentioned clinics will be collected in a specially designed database which will allow us to extract the data in a simple and safe way used for statistical analyses. in clinical research.",[27,550,551],"Male Infertility","Sexual Medicine",[550,553,554],"urology","rare male cancer","2024-01-04",{"date":557,"type":36},"2024-01-05",{"date":559,"type":36},"2015-02-24",{"date":561,"type":21},"2045-01-31",{"name":538,"class":43},{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":11,"sex":81,"minAge":52,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":44},"100421112","quality-and-outcome-measurements-of-urological-patients-100421112","NCT04763538","Quality and Outcome Measurements of Urological Patients","Inclusion Criteria:\n\n* All patients treated at the study sites, signed informed consent\n\nExclusion Criteria:\n\n* No consent to record medical history",{"count":570,"type":21},2000,"Prospectively, all available parameters of urologic patients treated at the study sites will be acquired and stored in multilayered databases. Upon a given samples size, neuronal networks will be trained to define clinical endpoints. Beside uro-oncological patients also patients with other urological diseases will be enrolled.",[27],"2023-03-09",{"date":575,"type":36},"2023-03-10",{"date":577,"type":36},"2021-09-01",{"date":579,"type":21},"2028-04-30",{"name":581,"class":43},"Insel Gruppe AG, University Hospital Bern",{"id":583,"slug":584,"hasResults":11,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":590,"conditions":591,"keywords":592,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":600,"locationsCount":72},"100454714","canadian-cohort-of-convective-thermal-therapy-using-rezm-system-in-benign-prostatic-hyperplasia-bph-100454714","NCT05201131","Canadian Cohort of Convective Thermal Therapy Using Rezūm System in Benign Prostatic Hyperplasia (BPH).","Inclusion Criteria:\n\n* Male subjects of ≥ 18 years of age.\n* Primary diagnosis of Benign Prostate Hypertrophy (BPH).\n* Candidate for Rezūm therapy as per clinical decision of Investigator.\n* Willing and able to accurately complete the required questionnaires.\n* Willing and able to provide signed and dated informed consent\n\nExclusion Criteria:\n\n* Characteristics indicating a poor compliance with study protocol requirements.\n* Disease or other health condition that is not suitable for this study.\n* Unable or unwilling to provide signed informed consent.",{"count":589,"type":21},50,"To document the clinical outcome of Rezūm therapy for BPH patient in Canadian cohort.",[27],[593],"benigh prostate hypertrophy","2022-01-07",{"date":596,"type":36},"2022-01-21",{"date":598,"type":36},"2019-10-07",{"date":69,"type":21},{"name":601,"class":43},"Can-Am HIFU Inc.",{"id":603,"slug":604,"hasResults":11,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":611,"conditions":612,"keywords":613,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":620,"locationsCount":72},"100452314","aquablation-in-benign-prostatic-hyperplasia-in-canada-100452314","NCT05169892","Aquablation in Benign Prostatic Hyperplasia in Canada","Canadian Cohort of Aquablation, a Robotically Executed, Surgeon-guided, High-pressure Water Jet Ablation Therapy for Endoscopic Resection of Prostate Tissue, in Benign Prostatic Hyperplasia (BPH).","Inclusion Criteria:\n\n* Primary diagnosis of Benign Prostate Hypertrophy (BPH)\n* Male subjects of ≥ 18 years of age\n* Candidate for Aquablation therapy as per clinical decision of Investigator\n* Willing and able to accurately complete questionnaires\n* Willing and able to provide signed and dated informed consent\n\nExclusion Criteria:\n\n* Characteristics indicating a poor compliance with study protocol requirements.\n* Disease or other health condition that is not suitable for this study.\n* Unable or unwilling to provide signed informed consent.",{"count":610,"type":21},25,"To document the clinical outcome of Aquablation therapy for BPH patient in Canadian cohort.",[27],[593],"2021-12-09",{"date":616,"type":36},"2021-12-27",{"date":618,"type":36},"2019-10-09",{"date":69,"type":21},{"name":601,"class":43},{"id":622,"slug":623,"hasResults":11,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":119,"sex":81,"minAge":52,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":22,"phases":630,"briefSummary":631,"conditions":632,"keywords":648,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":4},"100354774","phase-1-safety-and-clinical-outcomes-with-amniotic-and-umbilical-cord-tissue-therapy-for-numerous-medical-conditions-100354774","NCT03899298","Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions","Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions","Inclusion Criteria:\n\n1. Age 18 and over.\n2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.\n3. Competent to understand the study protocol and provide voluntary informed consent.\n4. Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back\u002FNeck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.\n\nExclusion Criteria:\n\n1. Active Cancer\n2. Pregnancy, Lactating\n3. Severe Clotting disorder\n4. Myocardial Infarction less than six months ago.",{"count":629,"type":21},5000,[24],"To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.",[633,634,27,635,636,637,638,94,639,640,641,642,643,644,645,646,647],"Orthopedic Disorder","Neurologic Disorder","Erectile Dysfunction","Autoimmune Diseases","Renal Failure","Renal Insufficiency","Cardiac Event","Cardiomyopathies","CHF","Pulmonary Disease","COPD","Alzheimer Disease","Stroke","Neuropathy;Peripheral","Arthritis",[649,650,651,652,653,654,655,656],"stem cell therapy","umbilical stem cells","amniotic stem cells","stem cells","regenerative medicine","r3 stem cell","perinatal tissue","placenta stem cell","2019-08-20",{"date":659,"type":36},"2019-08-22",{"date":661,"type":21},"2019-09-01",{"date":663,"type":21},"2029-03-20",{"name":665,"class":666},"R3 Stem Cell","INDUSTRY"]